Hallakou-Bozec S - Search Results

1

Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model.

Vial G, Chauvin MA, Bendridi N, Durand A, Meugnier E, Madec AM, Bernoud-Hubac N, Pais de Barros JP, Fontaine É, Acquaviva C, Hallakou-Bozec S, Bolze S, Vidal H, Rieusset J. Vial G, et al. Diabetes. 2015 Jun;64(6):2254-64. doi: 10.2337/db14-1220. Epub 2014 Dec 31. Diabetes. 2015. PMID: 25552598

2

Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents.

Perry RJ, Cardone RL, Petersen MC, Zhang D, Fouqueray P, Hallakou-Bozec S, Bolze S, Shulman GI, Petersen KF, Kibbey RG. Perry RJ, et al. Am J Physiol Endocrinol Metab. 2016 Aug 1;311(2):E461-70. doi: 10.1152/ajpendo.00009.2016. Epub 2016 Jul 12. Am J Physiol Endocrinol Metab. 2016. PMID: 27406738 Free PMC article.

3

Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration.

Detaille D, Vial G, Borel AL, Cottet-Rouselle C, Hallakou-Bozec S, Bolze S, Fouqueray P, Fontaine E. Detaille D, et al. Cell Death Discov. 2016 Jan 18;2:15072. doi: 10.1038/cddiscovery.2015.72. eCollection 2016. Cell Death Discov. 2016. PMID: 27551496 Free PMC article.

4

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes.

Hallakou-Bozec S, Vial G, Kergoat M, Fouqueray P, Bolze S, Borel AL, Fontaine E, Moller DE. Hallakou-Bozec S, et al. Diabetes Obes Metab. 2021 Mar;23(3):664-673. doi: 10.1111/dom.14277. Epub 2020 Dec 29. Diabetes Obes Metab. 2021. PMID: 33269554 Free PMC article. Review.

5

Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action.

Hallakou-Bozec S, Kergoat M, Fouqueray P, Bolze S, Moller DE. Hallakou-Bozec S, et al. PLoS One. 2021 Feb 19;16(2):e0241651. doi: 10.1371/journal.pone.0241651. eCollection 2021. PLoS One. 2021. PMID: 33606677 Free PMC article.

6

Imeglimin preserves islet β-cell mass in Type 2 diabetic ZDF rats.

Hallakou-Bozec S, Kergoat M, Moller DE, Bolze S. Hallakou-Bozec S, et al. Endocrinol Diabetes Metab. 2020 Nov 7;4(2):e00193. doi: 10.1002/edm2.193. eCollection 2021 Apr. Endocrinol Diabetes Metab. 2020. PMID: 33855202 Free PMC article.

7

The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells.

Vial G, Lamarche F, Cottet-Rousselle C, Hallakou-Bozec S, Borel AL, Fontaine E. Vial G, et al. Endocrinol Diabetes Metab. 2021 Feb 23;4(2):e00211. doi: 10.1002/edm2.211. eCollection 2021 Apr. Endocrinol Diabetes Metab. 2021. PMID: 33855213 Free PMC article.

8

Deuterium-Stabilized (R)-Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity.

Jacques V, Bolze S, Hallakou-Bozec S, Czarnik AW, Divakaruni AS, Fouqueray P, Murphy AN, Van der Ploeg LHT, DeWitt S. Jacques V, et al. Among authors: hallakou bozec s. Hepatol Commun. 2021 Apr 10;5(8):1412-1425. doi: 10.1002/hep4.1723. eCollection 2021 Aug. Hepatol Commun. 2021. PMID: 34430785 Free PMC article.

9

Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis.

Gluais-Dagorn P, Foretz M, Steinberg GR, Batchuluun B, Zawistowska-Deniziak A, Lambooij JM, Guigas B, Carling D, Monternier PA, Moller DE, Bolze S, Hallakou-Bozec S. Gluais-Dagorn P, et al. Among authors: hallakou bozec s. Hepatol Commun. 2022 Jan;6(1):101-119. doi: 10.1002/hep4.1799. Epub 2021 Sep 7. Hepatol Commun. 2022. PMID: 34494384 Free PMC article.

10

Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.

Cusi K, Alkhouri N, Harrison SA, Fouqueray P, Moller DE, Hallakou-Bozec S, Bolze S, Grouin JM, Jeannin Megnien S, Dubourg J, Ratziu V. Cusi K, et al. Among authors: hallakou bozec s. Lancet Gastroenterol Hepatol. 2021 Nov;6(11):889-902. doi: 10.1016/S2468-1253(21)00300-9. Epub 2021 Sep 22. Lancet Gastroenterol Hepatol. 2021. PMID: 34560015 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

19 results

Search Page